ATE545429T1 - Modulation der neurotrophinaktivität;screeningsverfahren - Google Patents

Modulation der neurotrophinaktivität;screeningsverfahren

Info

Publication number
ATE545429T1
ATE545429T1 AT07118012T AT07118012T ATE545429T1 AT E545429 T1 ATE545429 T1 AT E545429T1 AT 07118012 T AT07118012 T AT 07118012T AT 07118012 T AT07118012 T AT 07118012T AT E545429 T1 ATE545429 T1 AT E545429T1
Authority
AT
Austria
Prior art keywords
methods
neurotrophin
modulation
modulating
activity
Prior art date
Application number
AT07118012T
Other languages
English (en)
Inventor
Anders Nykjer
Claus Munck Petersen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Application granted granted Critical
Publication of ATE545429T1 publication Critical patent/ATE545429T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
AT07118012T 2002-12-20 2003-12-19 Modulation der neurotrophinaktivität;screeningsverfahren ATE545429T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200201977 2002-12-20

Publications (1)

Publication Number Publication Date
ATE545429T1 true ATE545429T1 (de) 2012-03-15

Family

ID=32668626

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07118012T ATE545429T1 (de) 2002-12-20 2003-12-19 Modulation der neurotrophinaktivität;screeningsverfahren

Country Status (7)

Country Link
US (5) US8066997B2 (de)
EP (2) EP1891966B1 (de)
AT (1) ATE545429T1 (de)
AU (1) AU2003287930A1 (de)
DK (1) DK1891966T3 (de)
ES (1) ES2380055T3 (de)
WO (1) WO2004056385A2 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4276174B2 (ja) * 2002-09-24 2009-06-10 雅臣 伊豫 摂食障害の診断薬および検定方法
EP1891966B1 (de) 2002-12-20 2012-02-15 H. Lundbeck A/S Modulation der Neurotrophinaktivität;Screeningsverfahren
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
JP5713377B2 (ja) 2005-12-28 2015-05-07 ザ スクリプス リサーチ インスティテュート 薬物標的としての天然アンチセンスおよび非コードｒｎａ転写物
FR2896881B1 (fr) 2006-01-31 2008-04-18 Biomerieux Sa Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie
EP1840133A1 (de) * 2006-03-29 2007-10-03 Global Biotech Development Corp. Ltd. Neue immunomodulierende Oligopeptide
RS60019B1 (sr) 2006-12-21 2020-04-30 H Lundbeck As Modulacija aktivnosti proneurotrofina
EP2077278A1 (de) 2007-12-21 2009-07-08 Centre National de la Recherche Scientifique (CNRS) Peptid abgeleitet von Neurotensin-Rezeptor 3 und Anwendung zur Behandlung von psychiatrischen Erkrankungen
KR101614558B1 (ko) * 2008-04-27 2016-04-22 하. 룬드벡 아크티에셀스카브 인간 소르틸린의 결정 구조 및 소르틸린에 대한 리간드를 확인하기 위한 이의 용도
US20160359907A1 (en) * 2015-06-02 2016-12-08 Vmware, Inc. Automatically auditing virtual machines for security hardening compliance
DK2851084T3 (en) * 2008-05-22 2018-07-30 H Lundbeck As Modulation of Vps10p domain receptors for the treatment of cardiovascular disease
EP2307042B1 (de) * 2008-06-25 2014-03-26 H. Lundbeck A/S Modulierung des trpv : vps10p domänen-rezeptorsystems zur behandlung von schmerzen
US20100061981A1 (en) * 2008-08-15 2010-03-11 The Salk Institute For Biological Studies p75NTR MEDIATES EPHRIN-A REVERSE SIGNALING
US20120039865A1 (en) * 2008-08-19 2012-02-16 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
US20110189310A1 (en) * 2008-10-08 2011-08-04 Cornell University Small molecule modulators of prongf uptake
US8447409B2 (en) * 2008-10-15 2013-05-21 Cochlear Limited Electroneural interface for a medical implant
EP3165537A1 (de) * 2008-12-19 2017-05-10 H. Lundbeck A/S Modulation der vps-10-domänen-rezeptor-familie für die behandlung von psychischen und verhaltensstörungen
SG175436A1 (en) 2009-05-04 2011-12-29 Abbott Res Bv Antibodies against nerve growth factor (ngf) with enhanced in vivo stability
US20120301463A1 (en) 2009-09-30 2012-11-29 President And Fellows Of Harvard College Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products
JP2013532144A (ja) * 2010-06-14 2013-08-15 ハー・ルンドベック・アクチエゼルスカベット ＳｏｒＬＡとＧＤＮＦファミリーリガンド受容体の間の相互作用の調節
US20130115222A1 (en) * 2010-06-15 2013-05-09 Cornell University Methods of limiting microvascular damage following acute myocardial ischemia
EP2646468B1 (de) 2010-12-01 2018-07-25 AlderBio Holdings LLC Anti-ngf-zusammensetzungen und ihre verwendung
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
HK1210211A1 (en) 2012-03-15 2016-04-15 科纳公司 Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
CA2875783C (en) 2012-06-06 2018-12-11 Zoetis Llc Caninized anti-ngf antibodies and methods thereof
CN104774264B (zh) 2014-01-15 2018-09-14 上海易乐生物技术有限公司 抗人proBDNF单克隆抗体及其在疼痛中的作用
EP3099313B1 (de) * 2014-01-27 2021-04-21 Centre National De La Recherche Scientifique Retro-inverso-analoga von spadin-display-verstärkten antidepressivawirkungen
WO2016164608A1 (en) 2015-04-07 2016-10-13 Alector Llc Methods of screening for sortilin binding antagonists
SI3280441T1 (sl) 2015-04-07 2022-01-31 Alector Llc Protitelesa anti-sortilin in metoda njihove uporabe
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
EP3390435A1 (de) * 2015-12-18 2018-10-24 Aarhus Universitet Sorcs peptide und deren verwendungen
EP3504209A4 (de) * 2016-08-25 2020-04-29 Pharmatrophix Inc. Verfahren und verbindungen zur behandlung von alkoholkonsum bedingten störungen und damit verbundenen erkrankungen
FR3057266B1 (fr) * 2016-10-11 2021-05-21 Centre Nat Rech Scient Peptides derives du propeptide ntsr3 et leur utilisation dans le traitement de la depression
FR3057267A1 (fr) * 2016-10-11 2018-04-13 Centre National De La Recherche Scientifique - Cnrs - Procede de diagnostic/determination de l'efficacite de traitement de la depression
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
BR112020017701A2 (pt) 2018-03-12 2020-12-29 Zoetis Services Llc Anticorpos anti-ngf e métodos dos mesmos
LT3618928T (lt) 2018-07-13 2023-04-11 Alector Llc Anti-sortilino antikūnai ir jų panaudojimo būdai
WO2021046169A1 (en) 2019-09-03 2021-03-11 University Of Cincinnati Methods and compositions for the treatment of als
US20230312652A1 (en) * 2020-08-06 2023-10-05 Aarhus Universitet Novel peptides and uses thereof
WO2023152229A1 (en) 2022-02-09 2023-08-17 Teitur Trophics Aps Novel peptides

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1130192A (en) * 1914-01-19 1915-03-02 Erik Oeman Process of producing sulfite cellulose.
US5604202A (en) 1990-11-13 1997-02-18 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Use of NGF growth factors to treat drug-induced neuropathy
JPH07505124A (ja) 1991-11-08 1995-06-08 ザ ユニバーシティ オブ サザン カリフォルニア ニューロトロフィン活性増強のためのｋ−２５２化合物を含む組成物
US5468872A (en) 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
US6291247B1 (en) 1994-05-11 2001-09-18 Queen's University At Kingston Methods of screening for factors that disrupt neurotrophin conformation and reduce neurotrophin biological activity
US5728803A (en) * 1994-06-03 1998-03-17 Genentech, Inc. Pantropic neurotrophic factors
GB9608335D0 (en) 1996-04-23 1996-06-26 Univ Kingston Method of enhancing ngf-mediated neurite growth with low molecular weight analoues of p.75 ngfr 367-379
WO1998046254A1 (en) * 1997-04-11 1998-10-22 Roche Diagnostics Gmbh Ngf for the prevention of demyelination in the nervous system
ES2213861T3 (es) 1998-10-09 2004-09-01 Scil Proteins Gmbh Procedimiento de obtencion de ngf-beta activa.
IT1305294B1 (it) * 1999-01-29 2001-05-04 Alessandro Lambiase Uso del nerve growth factor nella terapia di patologie a carico deitessuti intraoculari.
SE9904863D0 (sv) * 1999-12-30 1999-12-30 Medscand Medical Ab New use
IL142707A0 (en) * 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand
ATE554784T1 (de) 2001-05-25 2012-05-15 Cornell Res Foundation Inc Hochaffiner ligand für p75 neurotrophin-rezeptor
EP1891966B1 (de) 2002-12-20 2012-02-15 H. Lundbeck A/S Modulation der Neurotrophinaktivität;Screeningsverfahren

Also Published As

Publication number Publication date
US8815808B2 (en) 2014-08-26
EP1891966B1 (de) 2012-02-15
EP1589988A2 (de) 2005-11-02
AU2003287930A1 (en) 2004-07-14
ES2380055T3 (es) 2012-05-08
US8066997B2 (en) 2011-11-29
EP1891966A1 (de) 2008-02-27
US20170158766A1 (en) 2017-06-08
WO2004056385A3 (en) 2004-11-11
US20120082671A1 (en) 2012-04-05
US20130164297A1 (en) 2013-06-27
US9605073B2 (en) 2017-03-28
US8986690B2 (en) 2015-03-24
US20070264195A1 (en) 2007-11-15
US20150232565A1 (en) 2015-08-20
WO2004056385A2 (en) 2004-07-08
DK1891966T3 (da) 2012-04-02
AU2003287930A8 (en) 2004-07-14

Similar Documents

Publication Publication Date Title
ATE545429T1 (de) Modulation der neurotrophinaktivität;screeningsverfahren
Lessmann et al. Neurotrophin secretion: current facts and future prospects
Aguayo et al. Degenerative and regenerative responses of injured neurons in the central nervous system of adult mammals
DE69939950D1 (de) Verwendung von neuregulin zur beeinflussung der herzmuskelfunktion
NZ335207A (en) Process to isolate recombinant human neurotrophin using hydrophobic chromatography resin
DE69717308D1 (de) Verwendung von cntf (ciliary neurotrophic factor) rezeptoraktivatoren fur behandlung von fettleibigkeit
DE69527525D1 (de) Verfahren zur Schachtelung von Datenrahmen, Übertragungsfehlerkorrekturanordnung und Modulator damit
DE69736976D1 (de) Mit Alzheimer Krankheit verknüpften Verfahren zur Diagnose, zur Herstellung von Medikamenten und zum Screenen von Substanzen sowie aus Beta-Amyloid abgeleiteten Peptiden
DE69525860D1 (de) Herstellung von zeolithen unter verwendung von organischem templat und amin
DE69631588D1 (de) Benzolpiperidine/pyrrolidine zur verbesserung synaptischer reaktion
DE69832730D1 (de) Methode zur behandlung von dopaminergen und gaba-nergen störungen
Unsicker et al. Co-activation of TGF-ss and cytokine signaling pathways are required for neurotrophic functions
ATE86097T1 (de) Mittel zur faerbung von haaren und anwendung desselben.
ATE329603T1 (de) Implantat mit immunisolierten stromazellen und deren verwendung
ATE345811T1 (de) Methoden zur verwendung von neurotrophin 3 (nt-3) zur behandlung von gastrointestinalen hypomobilitätsstörungen
ATE311448T1 (de) Menschliche neuronale acetylcholin-rezeptor verbindungen und methoden zu deren anwendung
DK1427830T3 (da) Bv8-nukleinsyrer og -polypeptider med mitogen aktivitet
ATE181549T1 (de) Verfahren zur herstellung von (s)-3-amino-1- substituiert-pirrolidine
DK0593516T3 (da) Fremgangsmåder til behandling af motorneuronsygdomme ved anvendelse af medlemmer af BDNF/NT-3/NGF-molekylfamilien
ATE341348T1 (de) Bioartifizielle, primär vaskularisierte gewebematrix und bioartifizielles, primär vaskularisiertes gewebe
Engelhardt et al. Differential effects of NT‐4, NGF and BDNF on development of neurochemical architecture and cell size regulation in rat visual cortex during the critical period
ATE288498T1 (de) Methoden zur inhibierung von helicobacter pylori
ATE210126T1 (de) 4-amino-6-substituierte mycophenolsäurederivate mit immunsuppressiver wirkung
DE68916099D1 (de) Vorrichtungen und Mittel zur auswendigen Anwendung von Substanzen an Tieren.
Ding et al. The role of inhibitory neurons in novelty sound detection in regular and random statistical contexts